GV Safety Assessment Platform (GVSAP), a trailblazer in integrated research and development services, has announced a significant partnership with Biocytogen, renowned for its advanced drug discovery technologies. This collaboration is set to empower Indian researchers with state-of-the-art tools and humanized research models, marking a major leap in biomedical research capabilities.
Expanding Access to Advanced Biomedical Tools
This strategic alliance grants unprecedented access to Biocytogen’s extensive range of services, including humanized models, off-the-shelf products, and gene-targeting solutions offered under the BioMice sub-brand. Located in Genome Valley, Hyderabad, GVSAP’s facility spans over 30,000 square feet and adheres to stringent AAALAC International and OECD-GLP standards, ensuring top-tier research integrity and animal welfare.
Kalyan Korisapati, Co-Founder & CEO of GV Research Platform (GVRP), expressed his enthusiasm about the partnership, highlighting its potential to drive forward biomedical innovation in India. “Our collaboration with Biocytogen marks a monumental milestone in our mission to propel biomedical innovation forward,” said Korisapati.
Strengthening India’s Biopharma R&D
Yuelei Shen, CEO of Biocytogen, also emphasized the transformative impact of the collaboration, particularly for India’s growing biopharma sector. “With India’s rising prominence in biopharma R&D, it’s a pivotal hub for advanced solutions like humanized mice,” Shen noted. By combining GVSAP’s robust infrastructure and Biocytogen’s cutting-edge genetic engineering expertise, the partnership is poised to catalyze significant advancements in scientific discoveries and expedite innovation in biomedical research.
This alliance not only enhances GVSAP’s and Biocytogen’s capabilities but also aligns with their shared commitment to advancing healthcare solutions through innovative research and development.
Discover more from Business-News-Today.com
Subscribe to get the latest posts sent to your email.
